2,8-Diazaspiro[4.5]decan-1-one

Catalog No.: 
ACHNDL604
CAS No.: 
546086-95-7
Molecular Formula: 
C8H14N2O
Molecular Weight: 
154.21
2,8-Diazaspiro[4.5]decan-1-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$404.00InquiryInquiry
250mg95%$504.00InquiryInquiry
1g95%$807.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,8-Diazaspiro[4.5]decan-1-one
IUPAC Name2,8-diazaspiro[4.5]decan-1-one
MDL No.MFCD12406551
Molecular FormulaC8H14N2O
Molecular Weight154.21
SMILESO=C1NCCC12CCNCC2
InChI KeyHHIOFHJYOIVJJK-UHFFFAOYSA-N
Synonym2,8-diazaspiro[4.5]decan-1-one;8-Diazaspiro[4.5]decan-1-one;1-Oxo-2,8-diazaspiro[4.5]decane;2,8-Diazaspiro[4.5]decan-1-one HCL Salt;2,8-diazaspiro[4.5]decan-1-one (HCL form);2,8-Diazaspiro[4,5]decane-1-one
CAS No.546086-95-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACHNDL604 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYIZX621 route compound structure diagram
    ACYIZX621268550-48-7In Stock
  2. Then
  3. ACHNDL604 route product structure diagram
    ACHNDL604546086-95-7
Inquiry

2. ACHNDL604 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACYIZX621 route compound structure diagram
    ACYIZX621268550-48-7In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. ACBAUS147 route compound structure diagram
    ACBAUS1472923-16-2In Stock
  6. Then
  7. ACHNDL604 route product structure diagram
    ACHNDL604546086-95-7
Inquiry

3. ACHNDL604 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHNDL604 route product structure diagram
    ACHNDL604546086-95-7
Inquiry

Comments (0)